efficacy, safety, and determination of abbv-383, a bcma bispecific antibody, in patients with rrmm
Published 3 months ago • 222 plays • Length 6:43
Download video MP4
Download video MP3
Similar videos
-
7:06
efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
7:44
ash23: abbv-383 bcma x cd3 bispecific antibody for relapsed/refractory myeloma | ravi vij, md, mba
-
7:25
updated phase 1 results of teclistamab, a bcma × cd3 bispecific antibody, in rrmm
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
4:57
how can the unique structure of the bispecific abbv-383 impact its safety and efficacy?
-
3:22
updated safety and efficacy results of abbv-383 | ravi vij, md, mba | ash 2023
-
5:27
uvea-ixa: exploring the use of ixazomib-based therapy in r/r myeloma outside of clinical trials
-
4:28
first-in-human study of tnb-383b, a bcma x cd3 bispecific t-cell redirecting antibody, in pts w/rrmm
-
3:23
updated safety and efficacy results of abbv-383, a novel bsab, in patients with r/r multiple myeloma
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
7:26
regn5458, a bcmaxcd3 bispecific monoclonal antibody, in a phase 1/2 1st-in-human study in rrmm pts
-
4:26
what are bispecific antibodies?
-
8:33
initial safety results for phase 2 magnetismm-3 trial presented at asco 2022
-
19:49
abbv-383 - upcoming myeloma treatment
-
4:17
evaluating the safety and efficacy of elranatamab in multiple myeloma
-
3:44
phase i study of teclistamab, a humanized bcma x cd3 bispecific antibody, in relapsed/refractory mm
-
3:20
phase i trial of a bcma-cd3 bispecific antibody in r/r myeloma
-
14:56
abbvie 383 - guest lecture
Clip.africa.com - Privacy-policy